Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04948749Recruiting
Stenting plus medication to prevent stroke from narrowed brain arteries
This trial tests whether placing a stent in a severely narrowed brain artery, along with aggressive medication, can prevent another stroke better than medication alone. It is for people who had a mild stroke within the last 30 days due to a 70-99% blockage in a major brain artery.
Beijing, Beijing MunicipalityAges 18–85 - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT04977375RecruitingPhase 1/Phase 2
Anti–PD-1 treatment plus focused radiation for recurrent glioblastoma
This trial tests a cancer-immunotherapy medicine (an anti–PD-1 antibody, similar to pembrolizumab) combined with precisely targeted radiation to treat glioblastoma that has come back or progressed. It may help your immune system recognize and attack the tumor while the radiation targets the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04975152RecruitingPhase 1
Cemiplimab before surgery for Merkel cell and skin cancers
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Tampa, FloridaAges 18 years+ - NCT04892303RecruitingPhase 1
Planning treatment using radiation plus radioactive iodine for thyroid cancer
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
Baltimore, MarylandAges 18–85 - NCT04903795RecruitingPhase 1
Testing a targeted immune therapy for EGFR-mutant glioblastoma
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT04857502RecruitingEarly Phase 1
Tracking prostate cancer spread before lymph node surgery
This early study uses a special imaging tracer to show where prostate cancer has spread in the pelvic lymph nodes. It may help doctors better understand how well certain scans guide surgical removal of affected lymph nodes.
Los Angeles, CaliforniaAges Any age - NCT04906096RecruitingPhase 2
Paxalisib for repeat or resistant brain lymphoma
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
Boston, MassachusettsAges 18 years+ - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Birmingham, AlabamaAges 50–70 - NCT04797767RecruitingPhase 1/Phase 2
Venetoclax plus CLAG-M for high-risk AML
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Seattle, WashingtonAges 18 years+ - NCT04774393RecruitingPhase 1/Phase 2
Study for AML after it returns or resists treatment
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Houston, TexasAges 18 years+ - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04731610Recruiting
Radiation after thymoma surgery versus watchful waiting
This trial compares two approaches after complete surgical removal of stage IIb or III thymoma: targeted radiation (conformal post-operative radiotherapy) or no further treatment right away (surveillance). It aims to see whether adding radiation lowers the risk of the cancer coming back without causing unacceptable side effects.
CaenAges 18–75 - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT04645602RecruitingPhase 2
Study of pembrolizumab and lenvatinib for lung papillomas
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
New Haven, ConnecticutAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04545957Recruiting
Radiation planning study using MRI for adults with cancer
This trial tests a “master protocol” approach to use MRI (a detailed body scan) to help plan radiation treatment for people with cancer. It may help doctors customize radiation more accurately, depending on your specific cancer type.
Boston, MassachusettsAges 18 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT04547777RecruitingPhase 1
Early Phase brain tumor treatment with implanted device and injections
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT04587687RecruitingPhase 2
Brentuximab plus bendamustine for relapsed follicular lymphoma
This Phase 2 trial studies the combination of brentuximab vedotin and bendamustine in people whose follicular lymphoma has come back or did not respond. It aims to shrink the lymphoma and improve outcomes after at least one prior treatment.
Sacramento, CaliforniaAges 18 years+
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,384 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.